Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioquell Regulatory News (BQE)

  • There is currently no data for BQE

Disposal

25 May 2018 08:05

RNS Number : 3133P
Bioquell PLC
25 May 2018
 

 

 

 

 

25 May 2018

Bioquell PLC - Disposal of Defence Business

Bioquell PLC ("Bioquell") (LSE symbol: BQE) - a leading provider of products and services for the Life Sciences, Pharmaceutical and Healthcare markets today announces the disposal of its MDH Defence business ("MDH").

Under the terms of the disposal, MDH is being sold for an initial consideration of £0.4m, with a further contingent payment of up to £0.6m due if MDH is successful in winning a specific contract for which it is presently bidding within the next 12 months. Bioquell will complete a partly fulfilled defence contract which will generate revenue and margin of approximately £0.7m and £0.2m respectively during the second half of 2018.

In the year ended 31 December 2017, MDH had revenue of £0.7m and made an operating loss of £35,000. The value of MDH's net assets being disposed of at completion is £0.4 million and any gain or loss on disposal will not be material, save to the extent that contingent consideration is received. MDH has no shared products or shared customers with Bioquell's core business.

 

Commenting on the strategic disposal, Ian Johnson, Executive Chairman of Bioquell PLC, said:

"I am pleased to have been able to reach agreement to exit this non-core business. The disposal represents a further step in simplifying and reducing the complexity of the business and transitioning Bioquell's focus to its core products and services, namely; bio-decontamination, aseptic workstations and infection control enclosures."

Enquiries:

Ian Johnson Executive Chairman Bioquell PLC 01264 835900

Michael Roller Finance Director

 

***********************************************

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DISAAMRTMBMTMJP
Date   Source Headline
10th Mar 20087:00 amRNSFinal Results
9th Nov 200710:27 amRNSHolding(s) in Company
26th Oct 200710:13 amRNSSuperbug update.
2nd Oct 20071:29 pmRNSContract Award
12th Sep 20077:01 amRNSInterim Results
28th Jun 20073:38 pmRNSExercise of Options
11th Apr 20078:06 amRNSDirector/PDMR Shareholding
27th Mar 20078:48 amRNSDirector/PDMR Shareholding
27th Mar 20078:43 amRNSDirector/PDMR Shareholding
26th Mar 20077:01 amRNSFinal Results
21st Dec 200610:54 amRNSTotal Voting Rights
12th Dec 200611:39 amRNSHolding(s) in Company
19th Sep 20067:00 amRNSInterim Results
21st Aug 20061:43 pmRNSResult of EGM
19th Jul 200612:27 pmRNSNotice of EGM
2nd May 20069:55 amRNSDirector/PDMR Shareholding
27th Apr 20061:48 pmRNSAdditional Listing
11th Apr 20067:00 amRNSFinal Results
22nd Mar 20067:00 amRNS.Superbug. eradication trial
21st Dec 20057:00 amRNSResearch Update
26th Oct 20054:42 pmRNSAcquisition
26th Sep 20057:01 amRNSInterim Results
20th Apr 20052:27 pmRNSDirector Shareholding
15th Apr 20053:33 pmRNSHolding(s) in Company
11th Apr 20057:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.